學術研究成果/Publication
|
基本資料/Profiles
|
姓名/Name: |
黃志平
|
性別/Gender: |
男
|
英文姓名/ English Name: |
Chi-Ping Huang
|
英文縮寫/ Abbreviation: |
|
任職單位/ Affiliation: |
1.醫學院醫學系學士班泌尿學科(副教授) / Department of Urology (Associate Professor) 2.中國附醫泌尿部(部主任) / Department of Urology (Director-General)
|
Email: |
huangchiping@yahoo.com.tw
|
研究專長/Fields of Specialty
|
1﹒ |
泌尿腫瘤
|
2﹒ |
微創手術
|
3﹒ |
腎臟移植
|
4﹒ |
細胞治療
|
|
期刊論文/Journal Paper (作者群,論文題目,期刊名稱,出版年月,卷號(期別):頁次起迄)
|
SCI論文 |
王又德(Yu-De Wang)、黃志平(Chi-Ping Huang)、楊有容(You-Rong Yang)、吳錫金(Hsi-Chin Wu)、徐右儒(HSU YU-JU)、葉依純(Yi-Chun, Yeh)、葉佩純(Pei-Chun,Yeh)、吳國禎(Kuo-Chen Wu)、高嘉鴻(Chia-Hung Kao)*,Machine Learning and Radiomics of Bone Scintigraphy: Their Role in Predicting Recurrence of Localized or Locally Advanced Prostate Cancer,Diagnostics,2023 Nov,13(21):3380
|
SCI論文 |
石志榮(Chih-Rong Shyr)、劉良智(Liang-Chih Liu)、簡惠珊(CHIEN, HUI-SHAN)、黃志平(Chi-Ping Huang)*,Immunotherapeutic Agents for Intratumoral Immunotherapy,Vaccines,2023 Nov,11(11):
|
SCI論文 |
曾浩翔(CHEN HAO XIANG)、黃志平(Chi-Ping Huang)*,Oncological and functional outcome of robotic-assisted radical cystectomy with total intracorporeal stentless J-pouch neobladder reconstruction,International Journal of Medical Robotics and Computer Assisted Surgery,2023 Oct,20(1):2583
|
SCI論文 |
黃韋鈞(Wei-Chun Huang)、黃志平(Chi-Ping Huang)、賴俊鳴(Chun-Ming Lai)、顧芳瑜(Fang-Yu Ku)、許旭寧(Hsu-Ning Hsu)、楊朝棟(Chao-Tung Yang)、王韻儀(Yun-Yi Wang)、賴俊佑(Chun-Yo Laih)*,Increased intraoperative vein ligation in microsurgical varicocelecotmy is associated with pain improvement,MEDICINE,2023 Sep,102(38):35170
|
SCI論文 |
曾浩翔(CHEN HAO XIANG)、蔡禮賢(Li-Hsien,Tsai)、張兆祥(Chao-Hsiang Chang)、吳錫金(Hsi-Chin Wu)、林精湛(Ching-Chan Lin)、林哲弘(Che-Hung Lin)、葉士芃(Shih-Peng Yeh)、連啟舜(Chi-Shun Lien)、楊啟瑞(Chi-Rei Yang)、張議徽(Yi-Huei Chang)、梁基安(Ji-An Liang)、陳冠亨(Guang-Heng Chen)、蕭博任(Po-Jen Hsiao)、謝博帆(Hsieh, Po-Fan)*、黃志平(Chi-Ping Huang)*,Enzalutamide prior to radium-223 is associated with better overall survival in metastatic castration-resistant prostate cancer patients compared to abiraterone - a retrospective study,Cancers,2023 Jul,15(13):3516-3516
|
SCI論文 |
張家郡(Jhang, Jia- Jyun)、陳思如(Szu-Ju Chen)、黃志平(Chi-Ping Huang)、陳慧毅(Huey-Yi Chen)、林維卿(Wei-Ching Lin)、陳永祥(Chen, Yung-Hsiang)*、陳汶吉(Wen-Chi Chen)*,A Case Report of Intratesticular Hematoma in a Patient with Reiter’s Syndrome,Diagnostics,2023 Jun,13(12):1993
|
SCI論文 |
黃志平(Chi-Ping Huang)、盧欣麟(Hsin-Ling Lu)、石志榮(Chih-Rong Shyr)*,Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer,American Journal of Cancer Research,2023 Jun,13(6):2285-2306
|
SCI論文 |
賴建志(LAI CHIEN-ZHI)、(Szu-Ju Chen)、黃志平(Chi-Ping Huang)、陳慧毅(Huey-Yi Chen)、(Ming-Yen Tsai)、(Po-Len Liu)、陳永祥(Chen, Yung-Hsiang)*、陳汶吉(Wen-Chi Chen)*,Scrotal Pain after Varicocelectomy: A Narrative Review,Biomedicines,2023 Apr,11(4):1070-1070
|
SCI論文 |
徐明蔚(Ming-Wei, Hsu)、陳汶吉(Wen-Chi Chen)、魏廷娜(Ting-Na Wei)、黃志平(Chi-Ping Huang)*,Management of Enterovesical Fistula in a Patient with Crohn’s Disease: A Case Report and Literature Review,Diagnostics,2023 Apr,13(9):1527-1527
|
SCI論文 |
曾浩翔(CHEN HAO XIANG)、張詩欣(Shih-Hsin Chang)、陳得源(Der-Yuan Chen)、藍忠亮(Joung-Liang Lan)、楊凱介(Yeo Kai Jieh)、黃柏豪(Po-Hao Huang)、黃春明(Chung-Ming Huang)、黃志平(Chi-Ping Huang)、鄒頡龍(Chieh-Lung Chou)*、吳柏樟(Wu, Po-Chang)*,Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms—A randomized controlled trial,LUTS-Lower Urinary Tract Symptoms,2023 Apr,10(1111):
|
SCI論文 |
潘思穎(Szu-Ying Pan)、陳汶吉(Wen-Chi Chen)、黃志平(Chi-Ping Huang)、許重義(Chung Y Hsu)、張議徽(Yi-Huei Chang)*,The Association of Prostate Cancer and Urinary Tract Infections: A New Perspective of Prostate Cancer Pathogenesis,Medicina-Lithuania,2023 Mar,59():
|
SCI論文 |
張議徽(Yi-Huei Chang)、潘思穎(Szu-Ying Pan)、林佳瑜(LIN CHIA-YU)、黃志平(Chi-Ping Huang)、鍾季容(Chi-Jung Chung)、陳永祥(Chen, Yung-Hsiang)*、陳汶吉(Wen-Chi Chen)*,Factors Deciding Conservative or Intervention Treatment for Prostate Abscess: A Retrospective Case-Control Study,Journal of Personalized Medicine,2023 Mar,13():484
|
Other論文 |
黃志平(Chi-Ping Huang)、劉良智(Liang-Chih Liu)、盧欣麟(Lu, Hsin-Ling)、石志榮(Chih-Rong Shyr)*,Effects of hepatocyte growth factor on porcine mammary cell growth and senescence,BioMedicine,2023 Mar,13(1):13-21
|
Other論文 |
黃志平(Chi-Ping Huang)、劉良智(Liang-Chih Liu)、(Hsin-Ling Lu)、石志榮(Chih-Rong Shyr)*,Effects of Hepat ects of Hepatocyte Gr ocyte Growth Factor on P or on Porcine Mammar cine Mammary Cell Growth and Senescence,BioMedicine,2023 Mar,13(1):
|
SCI論文 |
潘思穎(Szu-Ying Pan)、賴建志(LAI CHIEN-ZHI)、陳汶吉(Wen-Chi Chen)、陳永祥(Chen, Yung-Hsiang)、林哲弘(Che-Hung Lin)*、張菡(Han Chang)、黃志平(Chi-Ping Huang)、葉進仲(Chin-Chung Yeh)*,Chondrosarcoma of Ureter in an Elderly Patient: A Case Report,Medicina-Lithuania,2023 Feb,59():454
|
SCI論文 |
謝博帆(Hsieh, Po-Fan)、李柏毅(LI PO-I)、林維卿(Wei-Ching Lin)、張菡(Han Chang)、張兆祥(Chao-Hsiang Chang)、吳錫金(Hsi-Chin Wu)、張議徽(Yi-Huei Chang)、王又德(Yu-De Wang)、黃文欽(Huang,Wen-Chin)*、黃志平(Chi-Ping Huang)*,Learning Curve of Transperineal MRI/US Fusion Prostate Biopsy: 4-Year Experience,Life-Basel,2023 Feb,13():638
|
SCI論文 |
(Pai-Yu Cheng)、(Hsiang-Ying Lee)、(Wei-Ming Li)、(Steven K Huang)、(Chien-Liang Liu)、(I-Hsuan Alan Chen)、(Jen-Tai Lin)、(Chi-Wen Lo)、(Chih-Chin Yu)、(Shian-Shiang Wang)、(Chuan-Shu Chen)、(Jen-Shu Tseng)、(Wun-Rong Lin)、(Jou Yeong-Chin)、(Ian-Seng Cheong)、(Yuan-Hong Jiang)、(Yu Khun Lee)、(Yung-Tai Chen)、(Shin-Hong Chen)、(Bing-Juin Chiang)、(Thomas Y Hsueh)、(Chao-Yuan Huang)、(Chia-Chang Wu)、(Wei Yu Lin)、(Yao-Chou Tsai)、(Kai-Jie Yu)、黃志平(Chi-Ping Huang)、(Yi-You Huang)、(Chung-You Tsai)*,Preoperative hydronephrosis is an independent protective factor of renal function decline after nephroureterectomy for upper tract urothelial carcinoma,Frontiers in Oncology,2023 Feb,13():
|
SCI論文 |
潘思穎(Szu-Ying Pan)、黃志平(Chi-Ping Huang)、陳汶吉(Wen-Chi Chen)、陳永祥(Chen, Yung-Hsiang)、鄒頡龍(Chieh-Lung Chou)*,Percutaneous Nephrolithotomy Combined Antegrade Flexible Ureteroscope for Complete Staghorn Stones: A Case Report of a New Concept of Stone Surgery,Medicina-Lithuania,2023 Jan,59(1):35-35
|
SCI論文 |
李柏毅(LI PO-I)、陳思如(Szu-Ju Chen)、陳永祥(Chen, Yung-Hsiang)、陳汶吉(Wen-Chi Chen)、黃志平(Chi-Ping Huang)*,Comparative Outcomes of Robotic Radical Prostatectomy in Patients with Locally Advanced Prostate Cancer,Medicina-Lithuania,2022 Dec,58():1820
|
SCI論文 |
(Changcheng Guo)、(Yin Sun)、(Wei Zhai)、(Xudong Yao)、(Dongkui Gong)、(Bosen You)、黃志平(Chi-Ping Huang)、(Junhua Zheng)*、張傳祥(Chawn-Shang Chang)*,Hypoxia increases RCC stem cell phenotype via altering the androgen receptor (AR)‑lncTCFL5‑2‑YBX1‑SOX2 signaling axis,Cell and Bioscience,2022 Nov,12(1):185
|
SCI論文 |
邱亮維(CHIU LIANG-WEI)、陳汶吉(Wen-Chi Chen)、謝博帆(Hsieh, Po-Fan)、陳永祥(Chen, Yung-Hsiang)、黃志平(Chi-Ping Huang)*,Efficacy and Complications of the Re-Adjustable Male Sling System for Stress Urinary Incontinence after Radical Prostatectomy,Journal of Clinical Medicine,2022 Nov,11():6764
|
SCI論文 |
張英傑(Chang Ying-Chieh)、陳思如(Szu-Ju Chen)、黃煒軒(Wei-Hsuan Huang)、黃志平(Chi-Ping Huang)、陳永祥(Chen, Yung-Hsiang)、陳汶吉(Wen-Chi Chen)*,Prostate Cancer after Percutaneous Arterial Embolization of the Prostate: A Case Report,Diagnostics,2022 Oct,12(10):2378
|
SCI論文 |
賴俊佑(Chun-Yo Laih)、蕭博任(Po-Jen Hsiao)、謝博帆(Hsieh, Po-Fan)、王又德(Yu-De Wang)、賴俊鳴(Chun-Ming Lai?)、楊朝棟(Chao-Tung Yang)、林祝興(Chu-Hsing Lin)、黃志平(Chi-Ping Huang)*,QSOFA and SOFA scores are valuable tools for predicting postoperative sepsis resulting from ureteroscopic lithotripsy (URSL),MEDICINE,2022 Oct,0():
|
SCI論文 |
潘思穎(Szu-Ying Pan)、黃志平(Chi-Ping Huang)、陳汶吉(Wen-Chi Chen)*,Synchronous/Metachronous Multiple Primary Malignancies: Review of Associated Risk Factors,Diagnostics,2022 Aug,12(8):
|
SCI論文 |
(Dong Chen)、(Fu-Ju Chou)、(Yuhchyau Chen)、黃志平(Chi-Ping Huang)、(Hao Tian)、(Yaqin Wang)、(Yuanjie Niu)、(Bosen You)、(Shuyuan Yeh)、(Nianzeng Xing)、(Chawnshang Chang)*,Targeting the radiation‑induced ARv7‑mediated circNHS/miR‑512‑5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity,JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,2022 Aug,41(1):235
|
SCI論文 |
(Qing Liu)、(Bosen You)、(Jialin Meng)、黃志平(Chi-Ping Huang)、(Guanglu Dong)、(Ronghao Wang)、(Fuju Chou)、(Shan Gao)、張傳祥(Chawn-Shang Chang)、(Shuyuan Yeh)*、(Wanhai Xu)*,Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling,CANCER GENE THERAPY,2022 Aug,():
|
SCI論文 |
(Min Tang)、(Yin Sun)、黃志平(Chi-Ping Huang)、(Lei Chen)、(Bianjiang Liu)、(Bosen You)、(Zengjun Wang)*、張傳祥(Chawn-Shang Chang)*,High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals,Cell Death & Disease,2022 Aug,13(8):746
|
SCI論文 |
方仁愷(Fang Jen Kai)、蕭博任(Po-Jen Hsiao)、邱鴻傑(Hung-Chieh Chiu)、黃志平(Chi-Ping Huang)*,Robot-Assisted Anatrophic Nephrolithotomy for complete staghorn stone,MEDICINE,2022 Jul,():
|
SCI論文 |
方仁愷(Fang Jen Kai)、蕭博任(Po-Jen Hsiao)、邱鴻傑(Hung-Chieh Chiu)、黃志平(Chi-Ping Huang)*,Robot-Assisted Anatrophic Nephrolithotomy for complete staghorn stone,MEDICINE,2022 Jul,():
|
SCI論文 |
李宗叡(Li Tzung-Ruei)、陳汶吉(Wen-Chi Chen)、黃志平(Chi-Ping Huang)*,Suprapubic transvesical mini-laparoscopy as an ideal approach for vesicovaginal fistula repair: Experiences from three patients,Asian Journal of Surgery,2022 Jun,45(11):2583-2584
|
SCI論文 |
謝博帆(Hsieh, Po-Fan)、張天佑(Tian-Yu Jhang)、林維卿(Wei-Ching Lin)、張菡(Han Chang)、張兆祥(Chao-Hsiang Chang)、黃志平(Chi-Ping Huang)、楊啟瑞(Chi-Rei Yang)、陳汶吉(Wen-Chi Chen)、張議徽(Yi-Huei Chang)、王又德(Yu-De Wang)、黃文欽(Huang,Wen-Chin)*、吳錫金(Hsi-Chin Wu)*,Saturation Target Biopsy can Overcome the Learning Curve of Magnetic Resonance Imaging/Ultrasound Fusion Biopsy of the Prostate,Journal of Mens Health,2022 May,18(6):127
|
SCI論文 |
(Henry H Woo)、黃志平(Chi-Ping Huang)、黃志賢(William J. H)、張議徽(Yi-Huei Chang)、連啟舜(Chi-Shun Lien)、(Archil Chkhotua)、(Dean S Elterman)*,The EXPANDER-1 trial: introduction of the novel Urocross™ Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH),PROSTATE CANCER AND PROSTATIC DISEASES,2022 May,0():
|
SCI論文 |
謝博帆(Hsieh, Po-Fan)、張天佑(Tian-Yu Jhang)、林維卿(Wei-Ching Lin)、張菡(Han Chang)、張兆祥(Chao-Hsiang Chang)、黃志平(Chi-Ping Huang)、楊啟瑞(Chi-Rei Yang)、陳汶吉(Wen-Chi Chen)、張議徽(Yi-Huei Chang)、王又德(Yu-De Wang)、黃文欽(Huang,Wen-Chin)*、吳錫金(Hsi-Chin Wu)*,A comparative study of transperineal software-assisted magnetic resonance/ ultrasound fusion biopsy and transrectal cognitive fusion biopsy of the prostate,BMC Urology,2022 Apr,22():72
|
SCI論文 |
(Hsiang-Ying Lee1)、張兆祥(Chao-Hsiang Chang)、黃志平(Chi-Ping Huang)、(Chih-Chin Yu)、(Chi-Wen Lo)、(Shiu-Dong Chung)、(Wei-Che Wu)、(I-Hsuan Alan Chen)、(Jen-Tai Lin1)、(Yuan-Hong Jiang)、(Yu-Khun Lee)、(Thomas Y. Hsueh)、(Allen W. Chiu)、(Yung-Tai Chen)、(Chang-Min Lin)、(Yao-Chou Tsai)、(Wei-Chieh Chen)、(Bing-Juin Chiang)、(Hsu-Che Huang)、(Chung-Hsin Chen)、(Chao-Yuan Huang)、(Chia-Chang Wu)、(Wei Yu Lin)、(Jen-Shu Tseng)、(Hung-Lung Ke)、(Hsin-Chih Yeh)*,Is Lymph Node Dissection Necessary During Radical Nephroureterectomy for Clinically Node-Negative Upper Tract Urothelial Carcinoma? A Multi-Institutional Study,Frontiers in Oncology,2022 Apr,12(791620):
|
SCI論文 |
歐世宸(Shi-Chen Ou)、黃升騰(Sheng-Teng Huang)、林美辰(Lin, Mei-Chen)、陳汶吉(Wen-Chi Chen)、黃志平(Chi-Ping Huang)、林宏任(Hung-jen Lin)*,Effects of Chinese herbal medicine in patients with benign prostatic hyperplasia: A nationwide cohort study in Taiwan,INTERNATIONAL JOURNAL OF UROLOGY,2022 Mar,2022():
|
SCI論文 |
(Lei Chen)、(Yin Sun)、(Min Tang)、(Denglong Wu)、(Zhendong Xiang)、黃志平(Chi-Ping Huang)、(Bosen You)、(Dongdong Xie)、(Qinglin Ye)、(Dexin Yu)、張傳祥(Chawn-Shang Chang)*,High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling,Cell Death Discovery,2022 Mar,8(1):128
|
SCI論文 |
(I-Hsuan Alan Chen)、張兆祥(Chao-Hsiang Chang)、黃志平(Chi-Ping Huang)、(Wen-Jeng Wu)、(Ching-Chia Li)、(Chung-Hsin Chen)、(Chao-Yuan Huang)、(Chi-Wen Lo)、(Chih-Chin Yu)、(Chung-You Tsai)、(Wei-Che Wu)、(Jen-Shu Tseng)、(Wun-Rong Lin)、(Yuan-Hong Jiang)、(Yu-Khun Lee)、(Yeong-Chin Jou)、(Ian-Seng Cheong)、(Thomas Y Hsueh)、(Allen W Chiu)、(Yung-Tai Chen)、(Jih-Sheng Chen)、(Bing-Juin Chiang)、(Yao-Chou Tsai)、(Wei Yu Lin)、(Chia-Chang Wu)、(Jen-Tai Lin)*、(Chia-Cheng Yu)*,Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan,Frontiers in Oncology,2022 Jan,11(766576):
|
SCI論文 |
黃志平(Chi-Ping Huang)、劉良智(Liang-Chih Liu)、(Chih-Chun Chang)、(Chun-Chie Wu)、石志榮(Chih-Rong Shyr)*,Intratumoral xenogeneic tissue-specific cell immunotherapy inhibits tumor growth by increasing antitumor immunity in murine triple negative breast and pancreatic tumor models,CANCER LETTERS,2021 Nov,():
|
SCI論文 |
謝博帆(Hsieh, Po-Fan)、李宗叡(LI TZUNG-RUEI)、林維卿(Wei-Ching Lin)、張菡(Han Chang)、黃志平(Chi-Ping Huang)、張兆祥(Chao-Hsiang Chang)、楊啟瑞(Chi-Rei Yang)、葉進仲(Chin-Chung Yeh)、黃文欽(Huang,Wen-Chin)、吳錫金(Hsi-Chin Wu)*,Combining prostate health index and multiparametric magnetic resonance imaging in estimating the histological diameter of prostate cancer,BMC Urology,2021 Nov,21():161
|
SCI論文 |
(Meng Zhang)、(Yin Sun)、黃志平(Chi-Ping Huang)、(Jie Luo)、(Li Zhang)、(Jialin Meng)、(Chaozhao Liang)*、張傳祥(Chawn-Shang Chang)*,Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression,Cell Death & Disease,2021 Sep,12(10):855
|
SCI論文 |
(Zai-Lin Sheu)、黃志平(Chi-Ping Huang)、(Chao-Hsiang Chang)、(Chung-Hsin Chen)、(Jian-Hua Hong)、(Han-Yu Weng)、(Ta-Yao Tai)、(Shiu-Dong Chung)、(Chi-Wen Lo)、(Thomas Y Hsueh)、(Yao-Chou Tsai)、(Yuan-Hong Jiang)、(Bing-Juin Chiang)、(Yung-Tai Chen)、(Jen-Tai Lin)、(Wei-Yu Lin)、(Yeong-Chin Jou)、(Jen-Shu Tseng)、(Chia-Chang Wu)、(Wen-Jeng Wu)、(Hsin-Chih Yeh)*,Tumor distribution affects bladder recurrence but not survival outcome of multifocal upper tract urothelial carcinoma treated with radical nephroureterectomy,Scientific Reports,2021 Sep,11(1):1905
|
SCI論文 |
(Gang Deng)、(Ronghao Wang)、(Yin Sun)、黃志平(Chi-Ping Huang)、(Shuyuan Yeh)、(Bosen You2)、(Changyong Feng)、(Gonghui Li2)、(Shenglin Ma)*、張傳祥(Chawn-Shang Chang)*,Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals,CELL DEATH AND DIFFERENTIATION,2021 Jul,28(2021):2145-2159
|
SCI論文 |
周聖峰(Sheng-Feng, Chou)、謝博帆(Po-Fan Hsieh)*、林維卿(Wei-Ching Lin)、黃志平(Chi-Ping Huang),Laparoscopic ureterolithotomy and retrograde flexible ureteroscopy-assisted transperitoneal laparoscopic ureteroureterostomy for a huge ureteropelvic junction stone and multiple small renal stones: A CARE-compliant case report,MEDICINE,2021 Jun,101():
|
SCI論文 |
黃志平(Chi-Ping Huang)、(Chi-Yu Yang)、石志榮(Chih-Rong Shyr)*,Utilizing xenogeneic cells as a therapeutic agent for treating diseases,CELL TRANSPLANTATION,2021 Apr,():
|
SCI論文 |
(Bosen You)、(Yin Sun)、(Jie Luo)、(Keliang Wang)、(Qing Liu)、(Ruizhe Fang)、(Bingmei Liu)、(Fuju Chou)、(Ronghao Wang)、(Jialin Meng)、黃志平(Chi-Ping Huang)、(Shuyuan Yeh)、張傳祥(Chawn-Shang Chang)*、(Wanhai Xu)*,Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR,ONCOGENE,2021 Mar,40(9):1674-1689
|
SCI論文 |
楊有容(You-Rong Yang)、陳思如(Szu-Ju Chen)、顏稟嶪(Yeh-Ping Yen)、黃志平(Chi-Ping Huang)、邱侶婷、林武周(Wu-Chou Lin)、陳慧毅(Huey-Yi Chen)、陳永祥(Yung-Hsiang Chen)、陳汶吉(Wen-Chi Chen)*,Hydronephrosis in patients with cervical cancer is an indicator of poor outcome,MEDICINE,2021 Feb,100(6):e24182
|
SCI論文 |
(Zhendong Xiang)、(Yin Sun)、(Bosen You)、(Meng Zhang)、黃志平(Chi-Ping Huang)、(Junfeng Yu)、(Xiangyun You)、(Denglong Wu)*、張傳祥(Chawn-Shang Chang)*,Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death,Cell Death & Disease,2021 Jan,12(1):68
|
SCI論文 |
(Hao Tian)、(Fu-Ju Chou)、(Jing Tian)、(Yong Zhang)、(Bosen You)、黃志平(Chi-Ping Huang)、(Shuyuan Yeh)、(Yuanjie Niu)*、張傳祥(Chawn-Shang Chang)*,ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling,JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,2021 Jan,40(1):3
|
SCI論文 |
黃志平(Chi-Ping Huang)、(Chun-Chie Wu)、石志榮(Chih-Rong Shyr)*,Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models,CANCER IMMUNOLOGY IMMUNOTHERAPY,2020 Dec,70():
|
SCI論文 |
(Lian-Ching Yu)、張兆祥(Chao-Hsiang Chang)、黃志平(Chi-Ping Huang)、(Chao-Yuan Huang)、(Jian-Hua Hong)、(Ta-Yao Tai)、(Han-Yu Weng)、(Chi-Wen Lo)、(Chung-You Tsai)、(Yu-Khun Lee)、(Yao-Chou Tsai)、(Thomas Y. Hsueh)、(Yao-Chou Tsai)、(I-Hsuan Chen)、(Bing-Juin Chiang)、(Jen-Shu Tseng)、(Chia-Chang Wu)、(Wei-Yu Lin)、(Tsu-Ming Chien)、(Zai-Lin Sheu)、(Ching-Chia Li)、(Hung-Lung Ke)、(Hsiang-Ying Lee)、(Hsiang-Ying Lee)、(Wen-Jeng Wu)、(Hsin-Chih Yeh)*,Prognostic Significance of Primary Tumor Location in Upper Tract Urothelial Carcinoma Treated with Nephroureterectomy: A Retrospective, Multi-Center Cohort Study in Taiwan,Journal of Clinical Medicine,2020 Nov,9(12):3866
|
SCI論文 |
黃志平(Chi-Ping Huang)、張兆祥(Chao-Hsiang Chang)、吳錫金(Hsi-Chin Wu)、楊啟瑞(Chi-Rei Yang)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、蕭博任(Po-Jen Hsiao)、張議徽(Yi-Huei Chang)、王又平(Yu-Ping Wang)、王又德(Yu-De Wang)*,External validation of the Simplified PADUA REnal (SPARE) nephrometry system in predicting surgical outcomes after partial nephrectomy,BMC Urology,2020 Sep,20(1):146
|
SCI論文 |
歐世宸(Shi-Chen Ou)、林美辰(Mei-Chen Lin)、林宏任(Hung-jen Lin)、黃志平(Chi-Ping Huang)、黃升騰(Sheng-Teng Huang)*,Association between erectile dysfunction and fibromyalgia in male patients: A Taiwanese nationwide population-based cohort study,INTERNATIONAL JOURNAL OF UROLOGY,2020 Sep,2020():
|
SCI論文 |
(Changyi Lin)、Fu-Ju Chou、(Jieyang Lu)、(Wanying Lin)、(Matthew Truong)、(Hao Tian)、(Yin Sun)、(Jie Luo)、(Rachel Yang)、(Yuanjie Niu)、(Rosa Nadal)、(Emmanuel S. Antonarakis)、(Carlos Cordon-Cardo)、(Deepak Sahasrabudhe)、黃志平(Chi-Ping Huang)、(Shuyuan Yeh)、(Gonghui Li)*、張傳祥(Chawn-Shang Chang)*,Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells,Aging-US,2020 Sep,12(17):17694-17712
|
SCI論文 |
(Qingbo Huang)、(Yin Sun)、(Wei Zhai)、(Xin Ma)、(Donglai Shen)、(Songliang Du)、(Bosen You)、(Yuanjie Niu)、黃志平(Chi-Ping Huang)、(Xu Zhang)*、張傳祥(Chawn-Shang Chang)*,Androgen receptor modulates metastatic routes of VHL wild-type clear cell renal cell carcinoma in an oxygen-dependent manner,ONCOGENE,2020 Sep,():
|
SCI論文 |
(Bianjiang Liu)、(Yin Sun)、(Min Tang)、(Chao Liang)、黃志平(Chi-Ping Huang)、(Yuanjie Niu)、(Zengjun Wang)*、張傳祥(Chawn-Shang Chang)*,The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer,Cell Death & Disease,2020 Sep,():
|
SCI論文 |
陳思如(Szu-Ju Chen)、黃志平(Chi-Ping Huang)、裘坤元(Kun-Yuan Chiu)、陳慧毅(Huey-Yi Chen)、邱侶婷、陳永祥(Yung-Hsiang Chen)、陳汶吉(Wen-Chi Chen)*,Association of acute pyelonephritis with double-J ureteral stenting:a nationwide population-based case control study,Scandinavian Journal of Urology,2020 Sep,():
|
SCI論文 |
(Hua Xua)、(Yin Sun)、(Bosen You)、黃志平(Chi-Ping Huang)、(Dingwei Ye)*、張傳祥(Chawn-Shang Chang)*,Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling,CANCER LETTERS,2020 Jul,472(2020):151-164
|
SCI論文 |
張議徽(Yi-Huei Chang)、蕭博任(Po-Jen Hsiao)、黃志平(Chi-Ping Huang)、吳錫金(Hsi-Chin Wu)、謝博帆(Po-Fan Hsieh)*、鄒頡龍(Chieh-Lung Chou)*,A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients,Toxins,2020 Jun,12(6):365-365
|
SCI論文 |
賴俊佑(Chun-Yo Laih)、黃志平(Chi-Ping Huang)、鄒頡龍(Chieh-Lung Chou)*,Labial adhesion in a postmenopausal female: a case report,MEDICINE,2020 May,20():
|
SCI論文 |
黃志平(Chi-Ping Huang)、(Liu LX)、石志榮(Chih-Rong Shyr)*,Tumor-associated Macrophages Facilitate Bladder Cancer Progression by Increasing Cell Growth, Migration, Invasion and Cytokine Expression,ANTICANCER RESEARCH,2020 May,40():2715-2724
|
SCI論文 |
(Junfei Gu)、(Yong Zhang)、(Zhenwei Han)、(Lei Gao)、(Jinfeng Cui)、(Yin Sun)、(Yuanjie Niu)、(Bosen You)、黃志平(Chi-Ping Huang)、張傳祥(Chawn-Shang Chang)、(Xiaolu Wang)*、(Shuyuan Yeh)*,Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC,Cell Death & Disease,2020 May,():
|
SCI論文 |
(Hua Xu)、(Yin Sun)、黃志平(Chi-Ping Huang)、(Bosen You)、(Dingwei Ye)*、張傳祥(Chawn-Shang Chang)*,Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation,Cancers,2020 Mar,():
|
SCI論文 |
(Jinbo Chen)、(Yin Sun)、(Zhenyu Ou)、(Shuyuan Yeh)、黃志平(Chi-Ping Huang)、(Bosen You)、(Yu-Chieh Tsai)、(Tzong-jen Sheu)、(Xiongbing Zu)*、張傳祥(Chawn-Shang Chang)*,Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion,EMBO REPORTS,2020 Feb,():
|
SCI論文 |
(Jinbo Chen)、(Fuju Chou)、(Shuyuan Yeh)、(Zhenyu Ou)、石志榮(Chih-Rong Shyr)、黃志平(Chi-Ping Huang)、(Zhendong Xiang)、(Yin Sun)、(Edward Messing)、(Xiongbing Zu)*、張傳祥(Chawn-Shang Chang)*,Androgen dihydrotestosterone (DHT) promotes the bladder cancer nuclear AR-negative cell invasion via a newly identified membrane androgen receptor (mAR-SLC39A9)-mediated Gαi protein/MAPK/MMP9 intracellular signaling,ONCOGENE,2020 Jan,():
|
SCI論文 |
(Keliang Wang)、(Jie Luo)、(Shuyuan Yeh)、(Bosen You)、(Jialin Meng)、(Philip Chang)、(Yuanjie Niu)、(Gonghui Li)、(Changxue Lu)、(Yezi Zhu)、(Emmanuel S. Antonarakis)、(Jun Luo)、黃志平(Chi-Ping Huang)、(Wanhai Xu)*、張傳祥(Chawn-Shang Chang)*,The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer,Nature Communications,2020 Jan,():
|
SCI論文 |
王又德(Yu-De Wang)、黃志平(Chi-Ping Huang)、張兆祥(Chao-Hsiang Chang)、吳錫金(Hsi-Chin Wu)、楊啟瑞(Chi-Rei Yang)、王又平(Yu-Ping Wang)、謝博帆(Po-Fan Hsieh)*,The role of RENAL, PADUA, C-index, CSA nephrometry systems in predicting ipsilateral renal function after partial nephrectomy,BMC Urology,2019 Aug,19(1):72
|
SCI論文 |
謝博帆(Po-Fan Hsieh)、李瑋涓(Li, Wei-Juan)、林維卿(Wei-Ching Lin)、張菡(Han Chang)、張兆祥(Chao-Hsiang Chang)、黃志平(Chi-Ping Huang)、楊啟瑞(Chi-Rei Yang)、陳汶吉(Wen-Chi Chen)、張議徽(Yi-Huei Chang)、吳錫金(Hsi-Chin Wu)*,Combining Prostate Health Index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population,WORLD JOURNAL OF UROLOGY,2019 Aug,.(.):.-.
|
SCI論文 |
黃志平(Chi-Ping Huang)、(Jinbo Chen)、(Chi-Cheng Chen)、(Guodong Liu)、(Yong Zhang)、(Edward Messing)、張傳祥(Chawn-Shang Chang)*,ASC-J9 (R) increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-B survival signals,JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH,2019 Jun,38(1):275-275
|
SCI論文 |
張議徽(Yi-Huei Chang)、蕭博任(Po-Jen Hsiao)、黃志平(Huang, Chi-Ping)*、沈德群(Te-Chun Shen)*,A Huge Cavity in the Right Upper Abdomen,BRITISH JOURNAL OF HOSPITAL MEDICINE,2019 Mar,80(3):173-173
|
SCI論文 |
黃志平(Chi-Ping Huang)、(Chi-Cheng Chen)、(Yi-Tung Tsai)、(Chun-Chie Wu)、石志榮(Chih-Rong Shyr)*,Intravesical Administration of Xenogeneic Porcine Urothelial Cells Attenuates Cyclophosphamide-Induced Cystitis in Mice,CELL TRANSPLANTATION,2019 Jan,1(1):1-10
|
SCI論文 |
謝博帆(Po-Fan Hsieh)、張兆祥(Chao-Hsiang Chang)、楊啟瑞(Chi-Rei Yang)、黃志平(Chi-Ping Huang)、陳汶吉(Wen-Chi Chen)、葉進仲(Chin-Chung Yeh)、鄒頡龍(Chieh-Lung Chou)、陳國樑(Kuo-Liang Chen)、連啟舜(Chi-Shun Lien)、陳冠亨(Guang-Heng Chen)、蕭博任(Po-Jen Hsiao)、張議徽(Yi-Huei Chang)、吳錫金(Hsi-Chin Wu)*,Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4e10 ng/mL,KAOHSIUNG JOURNAL OF MEDICAL SCIENCES,2018 Aug,34():461-466
|
SCI論文 |
黃志平(Huang, Chi-Ping)、(Chi-Cheng Chen)、石志榮(Shyr, Chih-Rong)*,Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses,Cancer Cell International,2018 Jan,18():9-16
|
SCI論文 |
(CHI-CHENG CHEN)、黃志平(Huang, Chi-Ping)、(YI-TUNG TSAI)、(TENG-FU HSEI)*、石志榮(Shyr, Chih-Rong)*,The Genomic Alterations of 5 alpha-Reductases and Their Inhibitor Finasteride's Effect in Bladder Cancer,ANTICANCER RESEARCH,2017 Dec,37(12):6893-6898
|
Other論文 |
陳冠亨(Guang-Heng Chen)、王曦賢(Hsi-Hsien Wang)、蕭博任(Po-Jen Hsiao)、張議徽(Yi-Huei Chang)、李聖偉(Sheng-Wei Li)、黃志平(Huang, Chi-Ping)、葉進仲(Yeh, Chin-Chung)、張兆祥(Chang, Chao-Hsiang)*,Evaluation of the relationship and postoperative glomerular filtration rate between the living donor and the recipients in kidney transplantation,Urological Science,2017 Dec,28(4):227-231
|
SCI論文 |
張兆祥(Chang, Chao-Hsiang)、邱鴻傑(Hung-Chieh Chiu)、林維卿(Lin, Wei-Ching)、何子龍(Tzu-Lung Ho)、張菡(Chang, Han)、張議徽(Yi-Huei Chang)、黃志平(Huang, Chi-Ping)、吳錫金(Wu, Hsi-Chin)、楊啟瑞(Yang, Che-Rei)、謝博帆(Po-Fan Hsieh)*,The Influence of Serum Prostate-Specific Antigen on the Accuracy of Magnetic Resonance Imaging Targeted Biopsy versus Saturation Biopsy in Patients with Previous Negative Biopsy,Biomed Research International,2017 Oct,2017():1-6
|
SCI論文 |
黃志平(Huang, Chi-Ping)、(CHI-CHENG CHEN)、石志榮(Shyr, Chih-Rong)*,The anti-tumor effect of intravesical administration of normal urothelial cells on bladder cancer,CYTOTHERAPY,2017 Sep,19():1233-1245
|
Other論文 |
連啟舜(Chi-Shun Lien)、李聖偉(Sheng-Wei Li)、張兆祥(Chang, Chao-Hsiang)、鍾季容(Chung, Chi-Jung)、林橙莉、黃志平(Huang, Chi-Ping)*,Adult balanoposthitis patients have a higher risk of type 2 diabetes mellitus: A nationwide population-based cohort study,Urological Science,2017 Sep,():
|
Other論文 |
王又德(Yu-De Wang)、張兆祥(Chao-Hsiang Chang)、黃志平(Chi-Ping Huang)、吳錫金(Hsi-Chin Wu)、楊啟瑞(Chi-Rei Yang)、謝博帆(Po-Fan Hsieh)*,New-generation nephrometry systems: head-to-head comparison of tumor contact surface area and resected and ischemic volume,Urological Science,2017 Aug,28():84-88
|
SCI論文 |
黃煒軒(Wei-Hsuan Huaug)、張兆祥(Chang, Chao-Hsiang)、黃志平(Huang, Chi-Ping)、吳錫金(Wu, Hsi-Chin)、謝博帆(Po-Fan Hsieh)*,The percentage of resected and ischemic volume determined by a geometric model is a significant predictor of renal functional change after partial nephrectomy,International Braz J Urol,2017 Jan,43(1):80-86
|
Other論文 |
蕭子玄(SIU JUSTIN JI-YUEN)、楊啟瑞(Che-Rei Yang)、張兆祥(Chang,Chao-Hsiang)、黃志平(Chi-Ping Huang)、吳錫金(Wu,Hsi-Chin)*,Salvage prostate cryoablation for recurrent localized prostate cancer after radiotherapy,Urological Science,2016 Dec,():
|
SCI論文 |
(Chi-Cheng Chen)、黃志平(Chi-Ping Huang)、(Wei-Kai Chiu)、(Wen-Ling Chang)、(Teng-Fu Hsieh)、石志榮(Chih-Rong, Shyr)*,Androgen receptor facilitates the recruitment of macrophages in tumor microenvironment to promote upper urinary tract urothelial cell carcinoma progression,American Journal of Cancer Research,2016 Sep,6(9):1922-1934
|
SCI論文 |
林詩怡(Shih-Yi Lin)、張兆祥(Chang,Chao-Hsiang)、吳錫金(Wu,Hsi-Chin)、林精湛(Ching-Chan Lin)、張凱博(Kai-Po Chang)、黃志平(Chi-Ping Huang)、徐武輝(Wu-Huei Hsu)、張志宗(Chiz-Tzung Chang)、陳朝榮(Chao-Jung Chen)*,Proteome Profiling of Urinary Exosomes Identifies Alpha 1-Antitrypsin and H2B1K as Diagnostic and Prognostic Biomarkers for Urothelial Carcinoma,Scientific Reports,2016 Sep,6():34446
|
SCI論文 |
謝博帆(Po-Fan Hsieh)、王又德(Yu-De Wang)、黃志平(Chi-Ping Huang)、吳錫金(Wu,Hsi-Chin)、楊啟瑞(Che-Rei Yang)、陳冠亨(Guang-Heng Chen)、張兆祥(Chang,Chao-Hsiang)*,A Mathematical Method to Calculate Tumor Contact Surface Area: An Effective Parameter to Predict Renal Function after Partial Nephrectomy,JOURNAL OF UROLOGY,2016 Jul,196(1):33-39
|
SCI論文 |
張兆祥(Chang,Chao-Hsiang)、劉秋松(Chiu-Shong Liu)、(Huei-Ju Liu)、黃志平(Chi-Ping Huang)、(Chao-Yuan Huang)、許惠悰(Hui-Tsung Hsu)、(Saou-Hsing Liou)、鍾季容(Chi-Jung Chung)*,Association between levels of urinary heavy metals and increased risk of urothelial carcinoma,INTERNATIONAL JOURNAL OF UROLOGY,2016 Mar,23(3):233-239
|
SCI論文 |
(Chi-Cheng Chen)、(Teng-Fu Hsieh)、黃志平(Chi-Ping Huang)、(Ai-Lin Yu)、(Wen-Lin Chang)、石志榮(Chih-Rong, Shyr)*,Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells,American Journal of Cancer Research,2016 Mar,6(2):238-248
|
Other論文 |
張凱博(Kai-Po Chang)、黃志平(Chi-Ping Huang)、張菡(Han Chang)*,Solitary renal metastasis of esophageal squamous cell carcinoma mimicking primary renal neoplasm – A case report and literature review,BioMedicine,2016 Mar,6(1):35-39
|
SCI論文 |
蕭博任(Po-Jen Hsiao)、謝博帆(Po-Fan Hsieh)、張兆祥(Chang,Chao-Hsiang)、吳錫金(Wu,Hsi-Chin)、楊啟瑞(Che-Rei Yang)、黃志平(Chi-Ping Huang)*,Higher risk of urothelial carcinoma in the upper urinary tract than in the urinary bladder in hemodialysis patients,RENAL FAILURE,2016 Mar,38(5):663-670
|
Other論文 |
張議徽(Yi-Huei Chang)、蕭博任(Po-Jen Hsiao)、陳冠亨(Guang-Heng Chen)、張兆祥(Chang,Chao-Hsiang)、陳汶吉(Chen, Wen-Chi)、葉進仲(Yeh, Chin-Chung)、黃志平(Chi-Ping Huang)*、鍾季容(Chi-Jung Chung)、鄒頡龍(Chieh-Lung Chou)、陳國樑(Chen, Kuo-Liang),Economic fluctuation affects vasectomy utilization: A single-institution study,Urological Science,2015 Sep,26(3):214-217
|
Other論文 |
張議徽(Yi-Huei Chang)、蕭博任(Po-Jen Hsiao)、陳冠亨(Guang-Heng Chen)、黃志平(Chi-Ping Huang)、吳錫金(Wu,Hsi-Chin)、楊啟瑞(Che-Rei Yang)、張兆祥(Chang,Chao-Hsiang)*,The value of cystography in the prediction of early urinary continence after radical prostatectomy,Urological Science,2015 Aug,():
|
SCI論文 |
連啟舜(Chi-Shun Lien)、黃志平(Chi-Ping Huang)、鍾季容(Chi-Jung Chung)、林橙莉、張兆祥(Chang,Chao-Hsiang)*,Increased risk of anxiety among patients with urolithiasis: A nationwide population-based cohort study,INTERNATIONAL JOURNAL OF UROLOGY,2015 Jul,0():
|
SCI論文 |
鍾季容(Chi-Jung Chung)、張兆祥(Chang,Chao-Hsiang)、褚志斌(Chih-Pin Chuu)、楊啟瑞(Che-Rei Yang)、張議徽(Yi-Huei Chang)、黃志平(Chi-Ping Huang)、陳汶吉(Chen, Wen-Chi)、(Mu-Chi Chung)、張菡(Han Chang)*,Reduced 5-Methylcytosine Level as a Potential Progression Predictor in Patients with T1 or Non-Invasive Urothelial Carcinoma,INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,2015 Jan,16():677-690
|
SCI論文 |
黃志平(Chi-Ping Huang)、(Teng-Fu Hsieh)、(Chi-Cheng Chen)、(Xiao-Fan Hung)、游艾琳(Ai-lin Yu)、張傳祥(Chawnshang Chang)、石志榮(Chih-Rong, Shyr)*,Anabolic androgens affect the competitive interactions in cell migration and adhesion between normal mouse urothelial cells and urothelial carcinoma cells,BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,2014 Oct,452():322-327
|
Other論文 |
謝博帆(Po-Fan Hsieh)、張兆祥(Chang,Chao-Hsiang)、楊啟瑞(Che-Rei Yang)、黃志平(Chi-Ping Huang)、陳至正(Chi-Cheng Chen)、陳國樑(Chen, Kuo-Liang)、張士三(Chang, Shi-San)、葉進仲(Yeh, Chin-Chung)、陳汶吉(Chen, Wen-Chi)、鄒頡龍(Chieh-Lung Chou)、吳錫金(Wu,Hsi-Chin)*,C index is associated with both short-term and long-term renal functional outcome after partial nephrectomy,Urological Science,2013 May,24(2):46-50
|
Other論文 |
張文馨(Wen-Shin Chang)、蔡佳紋(Chia-Wen Tsai)、鄭光皓(Kuang-Hao Cheng)、連啟舜(Chi-Shun Lien)、黃志平(Chi-Ping Huang)、廖文玲(Wen-Ling Liao)、李孟軒(Meng-Hsuan Lee)、吳錫金(Wu,Hsi-Chin)、張兆祥(Chang,Chao-Hsiang)、林正介(Cheng-Chieh Lin)、包大靝(Da-Tian Bau)*,The Role of APEX1/Ref-1 (apurinic/apyrimidic endonuclease DNA-repair gene) in Renal Cell Carcinoma,Adaptive Medicine,2012 Dec,4(4):216-223
|
SCI論文 |
謝博帆(Po-Fan Hsieh)、張兆祥(Chang,Chao-Hsiang)、黃志平(Chi-Ping Huang)、陳至正(Chen, Chi-Cheng)、陳國樑(Chen, Kuo-Liang)、張士三(Chang, Shi-San)、葉進仲(Yeh, Chin-Chung)、陳汶吉(Chen, Wen-Chi)、鄒頡龍(Chieh-Lung Chou)、吳錫金(Wu,Hsi-Chin)*,The impact of gender and size on the pathology of small renal mass,KAOHSIUNG JOURNAL OF MEDICAL SCIENCES,2012 Jul,28(7):369-372
|
SCI論文 |
林晏年(Yen-Nien Lin)、葉宏傑(Hung-Chieh Yeh)*、黃志平(Chi-Ping Huang)、江宜平(I-Ping Chiang),Wicked Benign Tumor in a Young Woman,Internal Medicine,2011 Sep,50(18):2069-2070
|
Other論文 |
黃志平(Chi-Ping Huang)、何君彥(Jiun-Yann Ho)、蘇重光(Chung-Kuang Su)、程千里(Chen-Li Cheng)、楊啟瑞(Chi-Rei Yang)*、葉致昌(Chih-Chang Yeh),Diagnosis and treatment of malignant extra-adrenal pheochromocytoma with presentation of bone pain and low urinary tract symptoms: A case report,台灣泌尿科醫學會雜誌,2009 Dec,20(4):184-187
|
|
研討會論文/Conference Papers (發表主題或論文名稱,研討會名稱,演講地點,研討會期間,受邀演講題目)
|
1﹒ |
腎臟移植後出現腔室症候群的案例分析,2023台灣內科醫學會會員大會暨學術演講會,台大醫院國際會議中心,2023.12.2 ~ 2023.12.3,
|
2﹒ |
腎移植後腔室症候群的個案分析及文獻回顧,台灣移植醫學學會2023移植年會暨教育訓練課程暨第二屆台韓交流論壇暨第三屆亞洲胰臟及胰島細胞移植學會會議,台北南港展覽館二館七樓,2023.12.9 ~ 2023.12.10,
|
3﹒ |
Comparison of the adverse events between 2 different BCG strains in patients receiving intravesical therapy for non-muscle invasive bladder urothelial carcinoma: A single center experience,2023 台灣泌尿科醫學會年會,台大國際會議中心,2023.8.19 ~ 2023.8.20,
|
4﹒ |
The role of SPARE nephrometry and tumor contact surface area in predicting malignancy and aggressiveness of clinical T1 tumors treated with partial nephrectomy,第110屆日本泌尿外科醫協會年會 (JUA),日本神戶,2023.4.20 ~ 2023.4.23,
|
5﹒ |
Mirabegron is more tolerable than solifenacin in Sjogren’s syndrome patients with OAB,38th Annual European Association of Urology Congress,米蘭,2023.3.10 ~ 2023.3.13,
|
6﹒ |
Focal high-intensity focused ultrasound (HIFU) therapy in low to intermediate-risk prostate cancer: preliminary outcomes in a single center,台灣泌尿科醫學會2023半年會,台北馬偕福容大飯店淡水漁人碼頭店,2023.2.4 ~ 2023.2.4,
|
7﹒ |
未打COVID19疫苗的腎移植病人確診後抗體反應仍不佳,2022台灣內科醫學會會員大會暨學術演講,台大醫院國際會議中心,2022.12.3 ~ 2022.12.4,
|
8﹒ |
台灣的腎臟移植患者注射新冠肺炎疫苗的效度分析,2022台灣移植醫學會年會,南港展覽館,2022.12.10 ~ 2022.12.11,
|
9﹒ |
HCV陰性的腎臟受贈者於接受HCV陽性的大愛腎臟移植術後三小時HCV病毒呈陽性-口服直接抗病毒藥應考慮即早使用,2022台灣移植醫學會年會,南港展覽館,2022.12.10 ~ 2022.12.11,
|
10﹒ |
The risk factors of the stress urinary incontinence after robotic- assisted laparoscopic radical prostatectomy,2022 台灣泌尿科醫學會年會,高雄萬豪酒店,2022.8.20 ~ 2022.8.21,
|
11﹒ |
Minimal invasive surgery for the treatment of ureteral endometriosis related obstructive uropathy – a single-center experience,2022 台灣泌尿科醫學會年會,高雄萬豪酒店,2022.8.20 ~ 2022.8.21,
|
12﹒ |
Bad-Luck but Good outcome: The clinical implications of synchronous prostate cancer and renal cell carcinoma in 5 cases,2022 台灣泌尿科醫學會年會,高雄萬豪酒店,2022.8.20 ~ 2022.8.21,
|
13﹒ |
體外震波碎石術後所造成腎臟血腫之相關分析,2022 TUA Annual Meeting,高雄萬豪酒店,2022.8.20 ~ 2022.8.21,
|
14﹒ |
,2021台灣泌尿科醫學會第22屆第2次會員大會暨第43次學術演講會-Live Surgery Demo.,台中榮民總醫院,2021.12.24 ~ 2021.12.26,
|
15﹒ |
The efficacy of the adjustable male sling system for stress urinary incontinence after radical prostatectomy,2021 台灣泌尿科醫學會年會,台中榮民總醫 院教學大樓 3F 會議室,2021.12.24 ~ 2021.12.26,
|
16﹒ |
Radium-223 for mCRPC: Real-world experience of a single-center,2021 台灣泌尿科醫學會年會,台中榮總,2021.12.25 ~ 2021.12.26,
|
17﹒ |
,Update of urologic oncology(視訊),沙童,2021.5.22 ~ 2021.5.22,
|
18﹒ |
Comparative Outcome of Robotic Radical Prostatectomy in Patients with Locally Advanced Prostate Cancer,台灣泌尿科醫學會2021半年會,基隆長庚醫院,2021.4.10 ~ 2021.4.10,
|
19﹒ |
Ureteral stent does not reduce incidence of acute kidney injury in patient receiving radical cystectomy and ileal urinary diversion,2021 泌尿科醫學會半年會,基隆長庚,2021.4.10 ~ 2021.4.10,
|
20﹒ |
,2021泌尿腫瘤論壇,嘉義長榮,2021.3.6 ~ 2021.3.7,
|
21﹒ |
Changes in Renal Function after Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma,2020 泌尿科醫學會年會,台大國際會議中心,2020.8.21 ~ 2020.8.23,
|
22﹒ |
The role of tumor contact surface area and SPARE nephrometry in predicting malignancy and aggressiveness of clinical T1 tumors treated with partial nephrectomy,2022 International Session of TUA Conference,高雄醫學大學,2020.8.20 ~ 2020.8.20,
|
23﹒ |
Robot-assisted radical cystectomy (RARC) with intracorporeal urinary diversion in female,台灣泌尿科醫學會2020年年會,臺大醫院國際會議中心, 台北,台灣,2020.8.21 ~ 2020.8.23,
|
24﹒ |
Neoadjuvant chemotherapy and adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma,台灣泌尿科醫學會年會,台大,2020.8.21 ~ 2020.8.23,
|
25﹒ |
Dual Kidney Transplantation: the Renal Graft Function Will Improve, Just Like a Sleeping Beauty Worth Waiting for,第三屆全球華人腎臟病學術大會,南京國際青年文化中心,2019.12.5 ~ 2019.12.8,
|
26﹒ |
Peripheral CD4 and CD8 Counts as guidance for Anti-ThymoGlobulin Dosage in Kidney Transplantation—A proposed new approach,Asia Pacific AKI to/on CKD Summit in conjunction with 台灣腎臟醫學會108年會員大會暨學術演講會,台大國際會議中心,2019.11.22 ~ 2019.11.24,
|
27﹒ |
endoscopic early realignment or delay urethral reconstruction for traumatic urethral total disruptuion: a single cencer experience,World Congress of Endourology 2019,Abu Dhabi National Exhibition Centre,2019.10.29 ~ 2019.11.2,
|
28﹒ |
ABO血型不相容活體腎臟移植-中國醫藥大學附設醫院經驗,109年台灣泌尿科醫學會年會,中國醫藥大學,2019.8.16 ~ 2019.8.18,
|
29﹒ |
銩雷射應用於大於80公克攝護腺刮除手術的使用治療經驗,108年度台灣泌尿科醫學會年會,台中中國醫藥大學立夫教學大樓5樓504室,2019.8.17 ~ 2019.8.18,
|
30﹒ |
Early endoscopic realignment for traumatic urethral total disruption- CMUH experience,TUA 2019,China Medical University Lifu Hall,2019.8.16 ~ 2019.8.18,
|
31﹒ |
Robotic Radical Prostatectomy for Locally Advanced Prostate Cancer (≥ pT3 or N1): Single Surgeon Experience,2019TUA第21屆第2次會員大會暨第41次學術演講會,中國醫藥大學附設醫院,2019.8.16 ~ 2019.8.18,
|
32﹒ |
Robotic partial nephrectomy for > 4cm Renal Cell Carcinoma: Single Center Experience,2019TUA第21屆第2次會員大會暨第41次學術演講會,中國醫藥大學附設醫院,2019.8.16 ~ 2019.8.18,
|
33﹒ |
Adjuvant chemotherapy in T3/T4 upper urinary tract urothelial carcinoma—CMUH experience,台灣泌尿科醫學會年會國際場 ISTUA,中國附醫,2019.8.16 ~ 2019.8.18,
|
34﹒ |
Outcome of lymph node dissection in renal pelvis urothelial carcinoma,台灣泌尿科醫學會年會,中國附醫,2019.8.16 ~ 2019.8.18,
|
35﹒ |
Robotic ureteroneocystostomy for distal ureteral obstruction: a single surgeon experience,日本泌尿科醫學會年會,日本名古屋,2019.4.18 ~ 2019.4.21,
|
36﹒ |
,2018 Post ESMO Highlights,与玥樓頂級粵菜餐廳(台中市南屯區公益路二段783號),2018.11.17 ~ 2018.11.17,Applications of precision medicine in GU cancer
|
37﹒ |
Robotic assisted laparoscopic nephroureterectomy with bladder cuff excision plus extended lymph node dissection for upper urinary tract urothelial cancer.,36th World Congress of Endourology,Paris, France,2018.9.20 ~ 2018.9.23,
|
38﹒ |
A case report: surgical management in a Crohn’s disease patient complicated with vesicoenteric fistula.,The International Section of Taiwan Urological Association Conference,Taipei Veterans General Hospital, Taiwan,2018.8.18 ~ 2018.8.18,
|
39﹒ |
Multiparametric Magnetic Resonance Imaging increases predictive accuracy of oncological outcomes after robot-assisted radical prostatectomy,台灣泌尿科醫學會年會,台北榮總,2018.8.18 ~ 2018.8.19,
|
40﹒ |
,Rational Decision Making in RCC: Knowledge, Hypothesis, and Hope,台中市南屯區公益路二段699號,2018.4.19 ~ 2018.4.19,STEP: Inlyta Dose Titration
|
41﹒ |
,學術研討會,名人坊(台中市西屯區台灣大道三段301號,新光三越4F),2018.3.29 ~ 2018.3.29,2018 ASCO GU updates in prostate cancer
|
42﹒ |
,中藥附設醫院泌尿外科RTD,台中市西區存中街22之1號,2018.1.31 ~ 2018.1.31,The timing and role of ADT in high risk prostate cancer
|
43﹒ |
Robotic-Assisted Partial Nephrectomy in a Single Surgeon Experience Peri- and Post-Operative Outcomes at a Mean of 24 Months Follow-Up,2018 TUA Midyear Meeting,彰化基督教醫院,2018.1.20 ~ 2018.1.20,
|
44﹒ |
,TUA 2017 (台灣泌尿科醫學學術研討會2017),高雄長庚紀念醫院,2017.8.19 ~ 2017.8.20,Active surveillance or definitive therapy for low risk localized prostate cancer (active surveillance)
|
45﹒ |
,106年癌症登記AJCC 8th教育訓練,中國醫藥大學立夫教學大樓國際會議廳 B1,2017.8.11 ~ 2017.8.11,AJCC 8th泌尿道癌分期解析(攝護腺、膀胱及腎臟癌)
|
46﹒ |
predictive markers for the prognosis of muscle invasive bladder cancer treated with neoadjuvant chemotherapy,泌尿科醫學會年會,高雄長庚,2017.8.19 ~ 2017.8.20,
|
47﹒ |
,泌尿照護議題研習會(中區),中國醫藥大學附設醫院癌症中心1樓階梯教室,2017.7.13 ~ 2017.7.13,泌尿系統癌症治療新趨勢
|
48﹒ |
,2017臺中攝護祭(民 眾衛教講座),中國醫藥大學 立夫教學大樓 104講堂,2017.6.25 ~ 2017.6.25,何時該接受攝護腺肥大手術,有哪些選擇?
|
49﹒ |
Comparison the prediective value of nephrometry systems in postoperative split renal function determined by renal scintigraphy: CSA, C-index, P.A.D.U.A., and R.E.N.A.L.,The 105th annual meeting of the Japanese Urological Association,Hotel Shiroyama, Kagoshima Prefectural Citizens Exchange Center, Houzan Hall,2017.4.21 ~ 2017.4.24,
|
50﹒ |
Debate: RP or RT on localized prostate cancer,台灣泌尿腫瘤醫學會攝泌尿癌研討會,高雄漢來大飯店 15 樓 會展廳 (高雄市成功一路266 號 TEL: 07-2135788),2016.12.10 ~ 2016.12.11,
|
51﹒ |
Comparison of Treatment of Large Proximal Ureteral Stones Laparoscopic Ureterolithotomy Versus Percutaneous Nephrolithotomy Versus Ureteroscopic Lithotripsy,WCE 2016,The Cape Town International Convention Centre, Cape Town, South Africa,2016.11.8 ~ 2016.11.12,URS outcomes
|
52﹒ |
Localized PC treatment in CMUH,2016 TUOA-Takeda Symposium,521 Teheranno, Gangnam-GU, 江南區 , 135732, 首爾 , 韓國,2016.9.9 ~ 2016.9.9,中國Management Sharing of Localized PC
|
53﹒ |
Local treatment for oligometastatic prostate cancer,雲嘉區攝護腺癌研討會,耐斯王子大飯店 嘉義市東區忠孝路600號 05- 2771999,2016.9.24 ~ 2016.9.24,
|
54﹒ |
Robot-Assisted Anatrophic Nephrolithotomy for complete staghorn stone: case series in China Medical University Hospital,104th Annual Meeting of the Japanese Urological Association,Sendai,2016.4.23 ~ 2016.4.25,Urolithiasis
|
55﹒ |
New-onset diabetes after kidney transplantation increased the risk of graft failure and macrovascular complications after kidney transplantation,2015台灣移植醫學年會,台北,2015.11.15 ~ 2015.11.15,
|
56﹒ |
A Milestone of Immuno‐Oncology 100 years development history and clinical application in bladder cancer,Non‐muscle‐invasive Bladder Cancer: Past, Present and Future,彰基福懋大樓 B1 國際培訓中心(彰化市建寶街20 號),2015.11.28 ~ 2015.11.28,BCG : A Milestone of Immuno‐Oncology 100 years development history and clinical application in bladder cancer
|
57﹒ |
How to establish a robotic programme?,Urology Symposium 2015,Prince of Wales Hospital, Hong Kong,2015.10.23 ~ 2015.10.24,Robotic surgery in Greater China
|
58﹒ |
Laparoscopic varicocelectomy: two trocars, one wound and one man.,World Congress of Endourology 2015,ExCeL London, UK,2015.10.1 ~ 2015.10.4,
|
59﹒ |
Gonadal vessels and inferior vesical artery sparing robotic nephroureterectomy with bladder cuff excision,2015 TUA Annual Meeting,花蓮慈濟醫院協力樓2樓和氣會議室,2015.8.21 ~ 2015.8.22,How to handle the challenging scenerio in robotic/laparoscopic surgery
|
60﹒ |
A review of systemic and localized therapy in aRCC,中區泌尿科月會,林酒店_上海廳 (台中市西屯區朝富路99號_台灣大道路口),2015.7.18 ~ 2015.7.18,
|
61﹒ |
Robotic partial nephrectomy (RCC)--- Live demonstration,泌尿腫瘤研討會,台中中國醫學大學附設醫院,2015.6.15 ~ 2015.6.15,
|
62﹒ |
Tips and tricks of robotic partial nephrectomy –experience in CMUH,2015中區泌尿月會 暨 Taiwan Preceptor Program on Renal Cell Carcinoma,中國醫藥大學 立夫教學大樓1樓104講堂,2015.6.13 ~ 2015.6.14,
|
63﹒ |
The concordance between pre-operative MRI and pathology stage in patients with prostate cancer underwent prostatectomy in CMUH,103rd Annual Meeting of the Japanese Urological Association,Kanazawa,2015.4.18 ~ 2015.4.21,Prostate cancer diagnosis
|
64﹒ |
Epidemiology of testicular tumors in Taiwan and subtype review – data from a medical center and Taiwan health insurance database,16th annual congress of Asia Pacific Association of Pediatric Urologists (APAPU 2014) 亞太小兒泌尿醫學會議,Nikko Japan , 日本日光,2014.11.20 ~ 2014.11.22,
|
65﹒ |
The Roles of da Vinci System and Laser for Super-enlarged Benign Prostate,GU DVD Forum研討會,日月潭大飯店,2014.11.15 ~ 2014.11.16,達文西for LUTS
|
66﹒ |
The role of GnRH-a in localized prostate cancer,台灣泌尿腫瘤醫學會冬季研討會,高雄義大皇家酒店7樓,2014.10.25 ~ 2014.10.25,
|
67﹒ |
,32nd World Congress of Endourology & SWL,Taipei International Convention Center (TICC) NO.1, Hsin-Yi Road, Sec 5, Taipei, Taiwan,2014.9.3 ~ 2014.9.7,
|
68﹒ |
roboitc surgery upper tract (上泌尿道機器手臂手術),第32屆世界泌尿內視鏡醫學大會(32nd World Congress of Endourology and SWL ),台北國際會議中心,2014.9.3 ~ 2014.9.7,roboitc surgery upper tract (上泌尿道機器手臂手術)
|
69﹒ |
PRIMARY ADRENAL INSUFFICIENCY WITH BILATERAL ADRENAL TUMOR: A CASE REPORT,台灣泌尿科醫學會年會,台北國際會議中心,2014.9.6 ~ 2014.9.7,
|
70﹒ |
THULIUM LASER VAPOENUCLEATION OF THE PROSTATE IN PATIENTS WITH EXCEPTIONALLY LONG PROSTATIC URETHRAS,World Congress of Endourology 2014,台北國際會議中心,2014.9.3 ~ 2014.9.7,
|
71﹒ |
The Role of Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: Exploring Sequential Therapy,台灣泌尿腫瘤醫學會秋季研討會,南投杉林溪大飯店,2014.8.16 ~ 2014.8.16,Sequential therapy for mRCC
|
72﹒ |
Robotic/Laparoscopic Partial Nephrectomy (機器手臂腎臟局部切除手術),103年手術室醫護聯合討論會,6C餐廳,2014.7.29 ~ 2014.7.29,
|
73﹒ |
Laparoscopic Procedures & Basic Principles,103年度泌尿科住院醫師核心訓練課程,台中榮民總醫院2樓會議室,2014.6.14 ~ 2014.6.14,
|
74﹒ |
,Prostatet cancer treatment conference,台中日月千禧酒店,2013.11.15 ~ 2013.11.15,cases sharing for localized prostate cancer
|
75﹒ |
,外科部11月份Grand Round,I棟階梯教室,2013.11.20 ~ 2013.11.20,達文西機器手臂之應用
|
76﹒ |
Preliminary Experience with da Vinci-assisted Laparoscopic Radical Prostatectomy in China Medical University Hospital,台灣泌尿科醫學會102年年會,義守大學教樓 義守大學教樓 A棟 1樓,2013.8.31 ~ 2013.8.31,
|
77﹒ |
達文西機器手臂手術的應用與發展,中國醫藥大學附設醫院全院學術演講,立夫醫療大樓21F國際會議,2013.7.6 ~ 2013.7.6,
|
78﹒ |
,泌尿科中區月會(5月),癌症大樓一樓會議室,2013.5.18 ~ 2013.5.18,達文西機器手臂輔助手術於中國醫藥大學附設醫院泌尿部之經驗
|
79﹒ |
,101年度腎臟移植座談會,癌症中心大樓一樓階梯教室,2012.12.28 ~ 2012.12.28,淺談腎移植
|
80﹒ |
,泌尿科醫療研討會,星月天空景觀餐廳,2012.11.17 ~ 2012.11.17,Changing Landscape for the Treatment of CRPC
|
81﹒ |
THE MUTUAL EFFECTS BETWEEN RENAL TRAUMA AND URETERAL STONE,台灣泌尿科醫學會年會,台大醫院國際會議中心,2012.8.17 ~ 2012.8.18,
|
82﹒ |
MANAGEMENT OF ENCASEMED AORTA AND INFERIOR VENA CAVA TO THE RETROPERITONEAL TUMOR: A CASE REPORT,台灣泌尿科醫學會年會,台大醫院國際會議中心,2012.8.17 ~ 2012.8.18,
|
83﹒ |
THE INITIAL MANIFESTATION OF RENAL CELL CARCINOMA IS PULMONARY EMBOLISM: A CASE REPORT,台灣泌尿科醫學會年會,台大醫院國際會議中心,2012.8.17 ~ 2012.8.18,
|
84﹒ |
,101年度台灣泌尿科醫學會年會,台大醫院國際會議中心,2012.8.18 ~ 2012.8.19,
|
85﹒ |
,攝護腺癌病友座談會暨成立大會,中國醫藥大學附設醫院 學校 立夫教學大樓1樓 103教室,2012.7.29 ~ 2012.7.29,攝護腺癌你、我、他--- 攝護腺癌病友會成立大會
|
86﹒ |
,膀胱腫瘤研討會,台中市大墩11街386號,2012.6.2 ~ 2012.6.2,Case sharing (BCG)
|
87﹒ |
,中區癌症醫學聯合學術研討會,南投縣鹿谷鄉內湖村興產路2-3號,2012.6.23 ~ 2012.6.24,Case presentation (RCC)
|
88﹒ |
,Post ELITE Seminar(中區泌尿科研討會),台中市大富街6 號,2012.5.18 ~ 2012.5.18,Lower Urinary Tract Symptoms due to BPH
|
89﹒ |
Prostate cancer: What's new in 2001 after EAU and AUA,Current advances in Prostate Cancer Treatment,台中亞緻大飯店27F,2011.10.1 ~ 2011.10.1,
|
90﹒ |
泌尿道保健,社區民眾衛教講座,台中市農會(台中市向上路一段95 號15 樓台中市農會會議室),2011.9.18 ~ 2011.9.18,
|
91﹒ |
Tricks and pitfalls of laparoscopic surgery,TUA100年泌尿科住院醫師核心課程講座,中國附醫癌症中心1F階梯教室,2011.7.23 ~ 2011.7.24,
|
92﹒ |
Dose it nedd for second TUR for high risk bladder cancer patient,七月份中區泌尿科醫學會膀胱腫瘤研討會,中山醫學大學正心樓,2011.7.16 ~ 2011.7.16,
|
93﹒ |
攝護腺癌治療後,PSA上升怎麼辦?,攝護腺癌醫療新知座談會,中國附醫癌症中心一樓階梯教室,2011.7.2 ~ 2011.7.2,
|
94﹒ |
攝護腺肥大,泌尿科醫學演講,天乙宮廣場(台中市東區天乙街50號),2011.1.23 ~ 2011.1.23,
|
95﹒ |
不能說的,民眾健康講座,台中縣豐原市豐勢路二段819巷40號,2010.9.30 ~ 2010.9.30,
|
96﹒ |
SINGLE-INCISION LAPAROSCOPIC SURGERY FOR TOTAL EXTRAPERITONEAL HERNIOPLASTY: THE INITIAL EXPERIENCE IN CHINA MEDICAL URINERSITY HOSPITAL,10th Asian Congress of Urology of the Urological Association of Asia,Taipei, Taiwan,2010.8.27 ~ 2010.8.31,
|
97﹒ |
TRANSUMBILICAL SINGLE-INCISION LAPAROSCOPIC ADRENALECTOMY: THE PRELIMINARY EXPERIENCE IN CHINA MEDICAL UNIVERSITY HOSPITAL,10th Asian Congress of Urology of the Urological Association of Asia,Taipei, Taiwan,2010.8.27 ~ 2010.8.31,
|
98﹒ |
COMPARISON OF RETROPERITONEAL LAPAROSCOPIC URETEROLITHOTOMY VERSUS RETROGRADE URETEROSCOPIC LITHOTRIPSY,10th Asian Congress of Urology of the Urological Association of Asia,Taipei, Taiwan,2010.8.27 ~ 2010.8.31,
|
99﹒ |
Laparoscopy,10th Asian Congress of Urology of the Urological Association of Asia,Taipei, Taiwan,2010.8.27 ~ 2010.8.31,Highlights of Previous Day
|
100﹒ |
,亞洲暨台灣泌尿科年會,台北國際會議中心,2010.8.27 ~ 2010.8.31,
|
101﹒ |
Update on the treatment strategy of LAPC,Update on LPC & LAPC,台中金典 13F 菁英二廳,2010.7.17 ~ 2010.7.17,Controversy in LAPC treatment
|
102﹒ |
SILS Application in Urology Field,Robotics & SILS Urology Surgery,Prince of Wales Hospital, Department of Surgery, Hong Kong,2010.7.30 ~ 2010.7.30,
|
103﹒ |
Green Light (KTP/HPS) laser prostatectomy,台灣泌尿科醫學會學術聯合研討會–中區 99年5月份,仁愛綜合醫院10F泉生大講堂台中縣大里市東榮路483號,2010.5.8 ~ 2010.5.8,
|
104﹒ |
單一切口腹腔鏡手術在泌尿科領域之應用,99年04月中區泌尿科月會,中國醫藥大學附設醫院 癌症中心大樓1樓階梯教室(台中市北區學士路6號),2010.4.24 ~ 2010.4.24,The Applications of Transumbilical Single-Incision Laparoscopic Surgery (SILS) in Urology Field
|
105﹒ |
以創新性單一傷口腹腔鏡膀胱切開取石手術及人工網膜疝氣修補手術治療一罕見巨大膀胱結石合併單側腹股溝疝氣:一病例報告(Vedio presentation),98年第16屆第2次會員大會暨第31次學術演講會,高雄榮民總醫院(高雄市大中一路386號,2009.8.29 ~ 2009.8.30,以創新性單一傷口腹腔鏡膀胱切開取石手術及人工網膜疝氣修補手術治療一罕見巨大膀胱結石合併單側腹股溝疝氣:一病例報告
|
106﹒ |
腎臟移植前評估及手術前後照顧,98年度腎臟移植座談會,中國醫藥大學附設醫院癌症中心大樓1樓階梯教室,2009.6.13 ~ 2009.6.13,
|
107﹒ |
Is PSA screen essentially for prostate cancer practice in Taiwan?,Consensus On Prostate Cancer Practice Guideline,台中裕元花園酒店4樓,2009.5.23 ~ 2009.5.23,
|
|
研究計畫/Research Grant (研究類型,研究計畫代號,主持人,補助或委託單位名稱,計畫名稱,研究經費,計畫期間)
|
1﹒ |
個別型,MOST 110-2314-B-039-026-MY3,黃志平(Chi-Ping Huang),石志榮(Chih-Rong Shyr),國科會,膀胱癌病灶內異種尿路上皮細胞免疫療法,$1130000,2021.8.1 ~ 2022.7.31
|
2﹒ |
個別型,DMR-110-009,林宏任(Hung-jen Lin),黃升騰(Sheng-Teng Huang)、黃志平(Chi-Ping Huang)、陳汶吉(Wen-Chi Chen),附醫院內計畫,攝護腺癌病患的中醫體質與特性評估分析:觀察性研究,$300000,2020.8.1 ~ 2021.7.31
|
3﹒ |
個別型,A1051222-107,趙坤山(Kun-San Chao),邱昌芳(Chang-Fang Chiu)、蔡銘修(Ming-Hsui Tsai)、陳自諒(Tzu-Liang Chen)、柯道維(Tao-Wei Ke)、王輝明(Hwei-Ming Wang)、陳宏彰(Hung-Chang Chen)、黃郁純(Yu-Chuen Huang)、花俊宏(Chun-Hung Hua)、張兆祥(Chao-Hsiang Chang)、楊啟瑞(Chi-Rei Yang)、吳錫金(Hsi-Chin Wu)、黃志平(Chi-Ping Huang)、蔡宗欣(Tzong-Shin Tzai)、張議徽(Yi-Huei Chang)、梁基安(Ji-An Liang)、簡君儒(Chun-Ru Chien)、吳建廷(Chen-Teng Wu)、劉良智(Liang-Chih Liu)、吳曜充(Yao-Chung Wu)、陳芝蓉(Chih-Jung Chen)、鄭書(Yu-Shu Cheng)、方信元(Hsin-Yuan Fang)、夏德椿(Te-Chun Hsia)、李嘉翔(Chia-Hsiang Li)、陳鴻仁(Hung-Jen Chen)、劉秋松(Chiu-Shong Liu)、陳毓隆(Yu-Lung Chen)、王中儀(JONG-YI WANG),衛福部,全方位癌症照護醫病共享決策輔助工具介入及其效益評估(106-107年) 107年後續擴充,$1803511,2018.10.5 ~ 2019.10.4
|
4﹒ |
臨床試驗與研究計畫,CMUH105-REC3-096,吳錫金(Wu, Hsi-Chin),楊啟瑞(Yang, Che-Rei)、張兆祥(Chang, Chao-Hsiang)、黃志平(Huang, Chi-Ping)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、葉士芃(Yeh, Su-Peng)、林精湛(Ching-Chan Lin)、林哲弘(Che-Hung Lin),附醫廠商計畫,ODM-201相較於安慰劑、加上標準雄性素去除療法與docetaxel使用於轉移性荷爾蒙敏感性攝護腺癌病患的一項隨機分配、雙盲、安慰劑對照第三期研究,$12175709,2017.1.1 ~ 2017.12.31
|
5﹒ |
臨床試驗與研究計畫,CMUH105-REC2-108,張兆祥(Chang, Chao-Hsiang),吳錫金(Wu, Hsi-Chin)、楊啟瑞(Yang, Che-Rei)、葉進仲(Yeh, Chin-Chung)、謝博帆(Po-Fan Hsieh)、連啟舜(Chi-Shun Lien)、陳冠亨(Guang-Heng Chen)、陳汶吉(Chen, Wen-Chi)、黃志平(Huang, Chi-Ping),附醫廠商計畫,一項研究亞洲攝護腺癌病患使用 ELIGARD®的安全性、療效和生活品質之第四期、介入性試驗(ELIGANT),$1110586,2017.1.1 ~ 2017.12.31
|
6﹒ |
臨床試驗與研究計畫,CMUH106-REC3-010,張兆祥(Chang, Chao-Hsiang),吳錫金(Wu, Hsi-Chin)、楊啟瑞(Yang, Che-Rei)、黃志平(Huang, Chi-Ping)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、林精湛(Ching-Chan Lin)、葉士芃(Yeh, Su-Peng),附醫廠商計畫,一項第III期、多中心、隨機分配、安慰劑對照、雙盲試驗,以ATEZOLIZUMAB (抗PD-L1抗體)作為輔助治療用於腎切除術後發生轉移風險偏高之腎細胞癌病患,$3864947,2017.1.1 ~ 2017.12.31
|
7﹒ |
臨床試驗與研究計畫,CMUH106-REC2-087,吳錫金(Wu, Hsi-Chin),張兆祥(Chang, Chao-Hsiang)、楊啟瑞(Yang, Che-Rei)、黃志平(Huang, Chi-Ping)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、張議徽(Yi-Huei Chang)、葉士芃(Yeh, Su-Peng)、林哲弘(Che-Hung Lin),附醫廠商計畫,一項第二期試驗,針對患有轉移性去勢療法無效之攝護腺癌,同時帶有DNA修復基因異常的男性患者,評估Niraparib的療效和安全性,$1698023,2017.1.1 ~ 2017.12.31
|
8﹒ |
臨床試驗與研究計畫,CMUH106-REC3-081,吳錫金(Wu, Hsi-Chin),張兆祥(Chang, Chao-Hsiang)、張議徽(Yi-Huei Chang)、楊啟瑞(Yang, Che-Rei)、黃志平(Huang, Chi-Ping)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、林哲弘(Che-Hung Lin)、葉士芃(Yeh, Su-Peng),附醫廠商計畫,一項第III期、隨機分配、雙盲、安慰劑對照的多中心試驗,針對無症狀或有輕度症狀且先前未曾接受治療的轉移性去勢抗性前列腺癌成人男性患者,給予IPATASERTIB併用ABIRATERONE和PREDNISONE/PREDNISOLONE或安慰劑併用ABIRATERONE和PREDNISONE/PREDNISOLONE進行比較,$2965257,2017.1.1 ~ 2017.12.31
|
9﹒ |
臨床試驗與研究計畫,CMUH106-REC2-071,張兆祥(Chang, Chao-Hsiang),吳錫金(Wu, Hsi-Chin)、楊啟瑞(Yang, Che-Rei)、黃志平(Huang, Chi-Ping)、葉士芃(Yeh, Su-Peng)、林精湛(Ching-Chan Lin)、陳冠亨(Guang-Heng Chen)、謝博帆(Po-Fan Hsieh)、林哲弘(Che-Hung Lin)、張議徽(Yi-Huei Chang)、林維卿(Lin, Wei-Ching),附醫廠商計畫,一項第三期、隨機分配、雙盲、安慰劑對照臨床試驗,以Pembrolizumab (MK-3475) 單一療法做為腎細胞癌腎切除術後的輔助性治療(KEYNOTE-564),$3565937,2017.1.1 ~ 2017.12.31
|
10﹒ |
臨床試驗與研究計畫,CMUH106-REC2-099,張兆祥(Chang, Chao-Hsiang),葉士芃(Yeh, Su-Peng)、吳錫金(Wu, Hsi-Chin)、張議徽(Yi-Huei Chang)、楊啟瑞(Yang, Che-Rei)、蕭博任(Po-Jen Hsiao)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、黃志平(Huang, Chi-Ping)、林哲弘(Che-Hung Lin)、林精湛(Ching-Chan Lin)、林維卿(Lin, Wei-Ching),附醫廠商計畫,一項隨機分配、雙盲、第2期試驗,評估腎細胞癌在接受一種血管內皮生長因子(VEGF)標靶治療後,使用二種不同起始劑量Lenvatinib (18mg相較於14mg QD)合併Everolimus (5mg QD)之安全性和療效,$4831661,2017.1.1 ~ 2017.12.31
|
11﹒ |
臨床試驗與研究計畫,CMUH106-REC2-121,張兆祥(Chang, Chao-Hsiang),吳錫金(Wu, Hsi-Chin)、楊啟瑞(Yang, Che-Rei)、陳冠亨(Guang-Heng Chen)、黃志平(Huang, Chi-Ping)、謝博帆(Po-Fan Hsieh)、張議徽(Yi-Huei Chang)、蕭博任(Po-Jen Hsiao)、葉士芃(Yeh, Su-Peng)、林哲弘(Che-Hung Lin),附醫廠商計畫,PARACHUTE:Pazopanib治療各種狀況晚期腎細胞癌患者之臨床療效及安全性實務評估;一項前瞻性、非介入性、觀察性研究,$233967,2017.1.1 ~ 2017.12.31
|
12﹒ |
臨床試驗與研究計畫,CMUH105-REC3-093,張兆祥(Chang, Chao-Hsiang),吳錫金(Wu, Hsi-Chin)、楊啟瑞(Yang, Che-Rei)、黃志平(Huang, Chi-Ping)、葉士芃(Yeh, Su-Peng)、林精湛(Ching-Chan Lin)、陳冠亨(Guang-Heng Chen)、謝博帆(Po-Fan Hsieh),附醫廠商計畫,一項第三期、隨機分配、開放性試驗,評估Pembrolizumab(MK-3475)併用Axitinib相較於Sunitinib單一療法做為局部晚期或轉移性腎細胞癌第一線療法的療效和安全性(KEYNOTE-426),$2941481,2017.1.1 ~ 2017.12.31
|
13﹒ |
臨床試驗與研究計畫,CMUH104-REC1-116,吳錫金(Wu, Hsi-Chin),梁基安(Liang, Ji-An)、陳汶吉(Chen, Wen-Chi)、陳冠亨(Guang-Heng Chen)、楊啟瑞(Yang, Che-Rei)、黃志平(Huang, Chi-Ping)、謝博帆(Po-Fan Hsieh)、葉進仲(Yeh, Chin-Chung)、郭于誠(Yu-Cheng, Kuo),附醫廠商計畫,接受主要放射線療法之高風險、局限性或局部晚期攝護腺癌受試者使用JNJ-56021927的一項隨機分配、雙盲、安慰劑對照第3期研究,$7331125,2017.1.1 ~ 2017.12.31
|
14﹒ |
臨床試驗與研究計畫,CMUH103-REC1-038,吳錫金(Wu, Hsi-Chin),張兆祥(Chang, Chao-Hsiang)、楊啟瑞(Yang, Che-Rei)、葉進仲(Yeh, Chin-Chung)、陳汶吉(Chen, Wen-Chi)、陳國樑(Chen, Kuo-Liang)、鄒頷龍、黃志平(Huang, Chi-Ping),附醫廠商計畫,第二期雙盲隨機分組安慰劑控制臨床試驗研究MCS®於預防男性前列腺癌之效果及安全性,$5762291,2017.1.1 ~ 2017.12.31
|
15﹒ |
臨床試驗與研究計畫,CMUH104-REC2-150,吳錫金(Wu, Hsi-Chin),張兆祥(Chang, Chao-Hsiang)、楊啟瑞(Yang, Che-Rei)、陳汶吉(Chen, Wen-Chi)、葉進仲(Yeh, Chin-Chung)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、連啟舜(Chi-Shun Lien)、黃志平(Huang, Chi-Ping),附醫廠商計畫,一項第三期隨機研究,針對接受確定性療法後其高風險非轉移性前列腺癌仍惡化的男性患者,探討 Enzalutamide + Leuprolide 療法、Enzalutamide 單一療法及安慰劑 + Leuprolide 療法的療效和安全性,$4329073,2017.1.1 ~ 2017.12.31
|
16﹒ |
臨床試驗與研究計畫,CMUH103-REC2-029,吳錫金(Wu, Hsi-Chin),張兆祥(Chang, Chao-Hsiang)、楊啟瑞(Yang, Che-Rei)、葉進仲(Yeh, Chin-Chung)、黃志平(Huang, Chi-Ping)、陳國樑(Chen, Kuo-Liang)、陳汶吉(Chen, Wen-Chi),附醫廠商計畫,一項亞洲、多國、第三期、隨機、雙盲、安慰劑對照、針對未曾接受化學治療且使用雄性素去除療法後失敗之漸進性轉移性攝護腺癌患者使用口服enzalutamide之療效與安全性的試驗,$4439602,2017.1.1 ~ 2017.12.31
|
17﹒ |
臨床試驗與研究計畫,CMUH103-REC2-031,吳錫金(Wu,Hsi-Chin),張兆祥(Chang,Chao-Hsiang)、陳汶吉(Chen, Wen-Chi)、葉進仲(Yeh, Chin-Chung)、楊啟瑞(Che-Rei Yang)、黃志平(Chi-Ping Huang),附醫廠商計畫,一項前瞻性、縱貫、多國參與、觀察性研究,描述在接受確定性攝護腺癌治療後經過生化檢測證明出現復發並具有臨床結果差的高風險的男性病人、患有抗去勢型攝護腺癌的男性病人,以及首次診斷即確定為轉移性攝護腺癌的男性病人的照護模式和結果,$60261,2016.1.1 ~ 2016.12.31
|
18﹒ |
臨床試驗與研究計畫,CMUH103-REC2-029,吳錫金(Wu,Hsi-Chin),張兆祥(Chang,Chao-Hsiang)、楊啟瑞(Che-Rei Yang)、葉進仲(Yeh, Chin-Chung)、黃志平(Chi-Ping Huang)、陳國樑(Chen, Kuo-Liang)、陳汶吉(Chen, Wen-Chi),附醫廠商計畫,一項亞洲、多國、第三期、隨機、雙盲、安慰劑對照、針對未曾接受化學治療且使用雄性素去除療法後失敗之漸進性轉移性攝護腺癌患者使用口服enzalutamide之療效與安全性的試驗,$4464250,2016.1.1 ~ 2016.12.31
|
19﹒ |
臨床試驗與研究計畫,CMUH103-REC1-038,吳錫金(Wu,Hsi-Chin),張兆祥(Chang,Chao-Hsiang)、楊啟瑞(Che-Rei Yang)、葉進仲(Yeh, Chin-Chung)、陳汶吉(Chen, Wen-Chi)、陳國樑(Chen, Kuo-Liang)、鄒頷龍、黃志平(Chi-Ping Huang),附醫廠商計畫,第二期雙盲隨機分組安慰劑控制臨床試驗研究MCS®於預防男性前列腺癌之效果及安全性,$900000,2016.1.1 ~ 2016.12.31
|
20﹒ |
臨床試驗與研究計畫,CMUH103-REC2-105,楊啟瑞(Che-Rei Yang),張兆祥(Chang,Chao-Hsiang)、葉進仲(Yeh, Chin-Chung)、吳錫金(Wu,Hsi-Chin)、黃志平(Chi-Ping Huang)、陳汶吉(Chen, Wen-Chi),附醫廠商計畫,一項開放性、單組試驗,以評估晚期前列腺癌受試者使用Leuprolide Mesylate注射液(LMIS 50mg)的安全性、療效與藥物動力學型態,$649755,2016.1.1 ~ 2016.12.31
|
21﹒ |
臨床試驗與研究計畫,CMUH103-REC1-135,吳錫金(Wu,Hsi-Chin),張兆祥(Chang,Chao-Hsiang)、楊啟瑞(Che-Rei Yang)、陳汶吉(Chen, Wen-Chi)、葉進仲(Yeh, Chin-Chung)、黃志平(Chi-Ping Huang)、葉士芃(Su-Peng Yeh)、林精湛(Ching-Chan Lin),附醫廠商計畫,一項第三期隨機臨床試驗,於患有已復發或已惡化轉移性尿路上皮癌的受試者中比較pembrolizumab(MK-3475)與paclitaxel、docetaxel或vinflunine,$1119213,2016.1.1 ~ 2016.12.31
|
22﹒ |
臨床試驗與研究計畫,CMUH104-REC2-030,吳錫金(Wu,Hsi-Chin),張兆祥(Chang,Chao-Hsiang)、楊啟瑞(Che-Rei Yang)、陳汶吉(Chen, Wen-Chi)、葉進仲(Yeh, Chin-Chung)、黃志平(Chi-Ping Huang)、 葉士芃、林精湛(Ching-Chan Lin)、林哲弘(Che-Hung Lin),附醫廠商計畫,一項使用Pembrolizumab (MK-3475)於晚期無法以手術切除或轉移性尿路上皮癌患者的第二期臨床試驗,$663450,2016.1.1 ~ 2016.12.31
|
23﹒ |
臨床試驗與研究計畫,CMUH104-REC2-150,吳錫金(Wu,Hsi-Chin),張兆祥(Chang,Chao-Hsiang)、楊啟瑞(Che-Rei Yang)、陳汶吉(Chen, Wen-Chi)、葉進仲(Yeh, Chin-Chung)、謝博帆(Po-Fan Hsieh)、陳冠亨(Guang-Heng Chen)、連啟舜(Chi-Shun Lien)、黃志平(Chi-Ping Huang),附醫廠商計畫,一項第三期隨機研究,針對接受確定性療法後其高風險非轉移性前列腺癌仍惡化的男性患者,探討 Enzalutamide + Leuprolide 療法、Enzalutamide 單一療法及安慰劑 + Leuprolide 療法的療效和安全性,$154661,2016.1.1 ~ 2016.12.31
|
24﹒ |
臨床試驗與研究計畫,CMUH105-REC2-091,張兆祥(Chang,Chao-Hsiang),葉士芃(Su-Peng Yeh)、林精湛(Ching-Chan Lin)、楊啟瑞(Che-Rei Yang)、吳錫金(Wu,Hsi-Chin)、陳冠亨(Guang-Heng Chen)、黃志平(Chi-Ping Huang),附醫廠商計畫,針對罹患局部晚期或轉移之泌尿上皮癌,完成第一線含鉑化學治療後無疾病惡化之患者,比較接受維持性治療Avelumab* (MSB0010718C)合併最佳支持性照護或單獨最佳支持性照護的一項第三期、多中心、多國、隨機分配、開放性、平行組別試驗,$694252,2016.1.1 ~ 2016.12.31
|
25﹒ |
臨床試驗與研究計畫,CMUH105-REC3-093,張兆祥(Chang,Chao-Hsiang),吳錫金(Wu,Hsi-Chin)、楊啟瑞(Che-Rei Yang)、黃志平(Chi-Ping Huang)、葉士芃(Su-Peng Yeh)、林精湛(Ching-Chan Lin)、陳冠亨(Guang-Heng Chen)、謝博帆(Po-Fan Hsieh),附醫廠商計畫,一項第三期、隨機分配、開放性試驗,評估Pembrolizumab(MK-3475)併用Axitinib相較於Sunitinib單一療法做為局部晚期或轉移性腎細胞癌第一線療法的療效和安全性(KEYNOTE-426),$533465,2016.1.1 ~ 2016.12.31
|
26﹒ |
個別型,DMR-104-045,黃志平(Chi-Ping Huang),附醫院內計畫,肥大細胞在膀胱癌進展上扮演的角色,$100000,2014.8.1 ~ 2015.7.31
|
27﹒ |
個別型,CMU102-BC-8,黃志平(Chi-Ping Huang),石志榮(Chih-Rong Shyr),本校(含附醫),以原位腫瘤異種移植動物模式研究男性荷爾蒙受體經由巨噬球在膀胱癌細胞的進展上扮演的角色,$200000,2014.5.1 ~ 2015.4.30
|
28﹒ |
個別型,DMR-101-054,黃志平(Chi-Ping Huang),禇志斌(Chih-Pin Chuu)、鍾季容(Chi-Jung Chung)、張兆祥(Chang,Chao-Hsiang),附醫院內計畫,系統性研究攝護腺癌惡化中之生物標誌,$150000,2011.8.1 ~ 2012.7.31
|
29﹒ |
個別型,DNR-99-159,黃志平(Chi-Ping Huang),張兆祥(Chang,Chao-Hsiang),附醫院內計畫,急性尿滯留對於男性病患血清中的攝護腺特異抗原數值之影響,$150000,2008.8.1 ~ 2009.6.30
|
|
獲獎/Award (獲獎名稱,給獎單位,獲獎日期)
|
1﹒ |
101年度最佳影片甄選第一名,台灣泌尿科醫學會,2012.08.18
|
2﹒ |
101年度最佳影片甄選第三名,台灣泌尿科醫學會,2012.08.18
|
|